logo-loader
VolitionRx

VolitionRx well funded as it advances development of its novel cancer tests

VolitionRx Limited (NYSEAmerican:VNRX) CEO Cameron Reynolds brings Proactive's Andrew Scott up to date on developments with their cancer blood tests as well as discussing the group's 2018 results.

As of the end of December, Volition's cash position stood at $13.4 million - up from $10.1 million at the close of 2017.

Reynolds says continued development of their Nu.Q Capture and Nu.Q Vet products coupled with the strengthening of the company's product pipeline beyond colorectal cancer will help them generate early revenue.

Quick facts: VolitionRx

Price: $4.01

Market: NYSEMKT
Market Cap: $164.77 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

VolitionRx reports strong second quarter as it moves forward on key MoUs

VolitionRx Limited's (NYSEAMERICAN:VNRX) Cameron Reynolds caught up with Proactive London's Andrew Scott to discuss the group's second quarter update. Reynolds says they've continued to strengthen the balance sheet with cash and cash equivalents increasing significantly thanks to warrant...

1 week, 4 days ago

2 min read